retatrutide clinical trial results 2024 New Obesity Drug Helped People Lose Nearly One-Third Their Body Weight Lilly's triple agonist, retatrutide, delivered

Compounded semaglutide at $199/month provides the best combination of effectiveness and affordability, producing 10-15% average weight loss at 85% less cost than brand-name Wegovy ($1,349/month)

Donovan, E

Image credit: niksdope/Shutterstock.com In a preliminary human study published in Scientific Reports , researchers investigated whether glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide (Ozempic), could alter the body's physiological and psychological response to alcohol

A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves disease

Karaer I, Akalin Y